Daiichi Sankyo Patent-Cliff Exposure & CMS Drug Spending Portfolio

Daiichi Sankyo (Basking Ridge, NJ): 12 reconciled FDA prescription therapies (12.6% 2025 to 2030 cliff risk), $371.9M 2024 CMS Part D & Medicaid spend, and 41 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterBasking Ridge, NJ
Reconciled FDA Portfolio Therapies12
2025 to 2030 Patent-Cliff Revenue Exposure12.6%
Primary Portfolio LOE Date2028-01-01
2024 CMS Total Public Spend$371.9M
2024 Medicare Part D Spend$26.2M
2024 Medicaid Spend$345.6M
California HCAI SB 17 Filings41 WAC filings (max 31.6% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Daiichi Sankyo across sibling Meru public-data platforms.